GC
RGLS

Globeflex Capital’s Regulus Therapeutics RGLS Stock Holding History

Globeflex Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-672
Closed -$233K – 534
2016
Q2 		$233K Sell
672
-485
-42% -$347K 0.06% 316
2016
Q1 		$962K Buy
+1,157
New +$920K 0.26% 140

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Globeflex Capital's RGLS Position: Q3 2016 in Review

Globeflex Capital sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 672 shares — an estimated $233K sold.

Globeflex Capital first reported a position in RGLS in Q1 2016 and held it in 2 quarters. The position peaked at $962K in Q1 2016. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

  • Globeflex Capital reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Globeflex Capital sold 672 Regulus Therapeutics shares in Q3 2016, an estimated $233K.
  • Globeflex Capital first reported a position in Regulus Therapeutics in Q1 2016 and held it in 2 quarters.
  • Globeflex Capital's Regulus Therapeutics position peaked at $962K in Q1 2016.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Globeflex Capital's 13F filing for Q3 2016, filed 9 Nov 2016.